Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is March 21, 2025, covering share purchases executed on March 20, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of GSK's existing share buyback programme.
Key Financial Metrics and Transaction Details
- Shares Purchased: 565,320 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,501.00 GBp; highest price paid was 1,522.00 GBp.
- Average Price: Volume-weighted average price paid was 1,512.49 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Shares: Following this purchase, GSK holds 181,950,290 ordinary shares in treasury.
- Shares in Issue: 4,133,255,002 ordinary shares (excluding treasury shares).
- Voting Rights: Total voting rights are 4,133,255,002.
Material Changes and Programme Progress
The purchase was effected pursuant to a non-discretionary agreement entered into with the broker on February 24, 2025. Since the inception of this specific agreement on February 24, 2025, the Company has purchased an aggregate of 12,879,987 ordinary shares. The filing does not provide comparative financial performance data (revenue, profit, or cash flow) as it is a disclosure of a specific capital transaction rather than a periodic financial report.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These factors are referenced as being described under "Risk factors" on pages 277 to 285 of the GSK 2024 Annual Report on Form 20-F. No new specific guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of treasury shares held (181,950,290) against the latest Form 20-F or subsequent filings to track buyback progress.
- Confirm the remaining authorization under the current buyback programme to assess future capital return potential.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for the detailed risk factors referenced in the cautionary statement.
- Monitor the London Stock Exchange for further daily disclosures regarding the non-discretionary buyback agreement initiated on February 24, 2025.